CXCL1 and pancreatic neuroendocrine tumor: Furthermore, when ENA-78/CXCL5 and GRO-α/CXCL1 levels were compared by R&E in other diagnoses from the FPC cohort (including pancreatic neuroendocrine tumors (PNET), intraductal papillary mucinous neoplasms (IPMN), and pancreatitis), NHB individuals continued to demonstrate significantly elevated baseline levels of these biomarkers compared to other R&E groups (Figure 4C).